ACIC Pharmaceuticals Inc.

Divi’s Laboratories Limited (Divi’s), is a pharmaceutical company headquartered in Hyderabad, India.
Divi’s is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies primarily for export to regulated markets such as US and Europe. With two manufacturing facilities, market presence across several countries and a team of 10,000 employees, Divi’s continues to innovate to bring robust techniques to facilitating sustainable manufacturing processes.

The company was founded in 1990 by Dr. Murali K Divi with research and development as its core area. Started initially as a Research and Development Center, it expanded and focused on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates, providing complete turnkey solutions and consulting to the domestic pharmaceutical industry.

Symphony was founded by eminent experts from Pharma Industry to create new bench mark in collaborative Research and Services.

Symphony provides Chemistry Services for:

 Chemistry support for early stage drug discovery molecules, building blocks & scaffolds, analogues & library compounds synthesis
 cGMP Kilo scale manufacturing & supply (up to 25Kg) of clinical drug substance (NCE) for preclinical to clinical studies
 CMC documentation & support for NDA submission
 Experience of working on more than 40 NCEs for our Global Innovator clients on FTE (Full Time Equivalent) & FFS (Fee For Service) client engagement models.
 Custom Synthesis from mg to kg for non-catalogue/expensive catalogue compounds
 Non-infringing and cost effective process development for generic APIs and intermediates and technical package submissions for commercial manufacturing
 Process validations under cGMP pilot plant
 Analytical (HPLC/GC) method development & validations


Symphony has expert team of Scientists and marketing professionals with an excellent track record of Research and timely delivery capabilities.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services – from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.

Our Discovery services include conducting early-stage research from target identification to delivery of drug candidates for further development. Development services encompass activities from pre-clinical to clinical trials including Drug Substance Development (DSP), Drug Product Development (DPD) and associated services to demonstrate safety, tolerability and efficacy of the selected drug candidate.

Our Manufacturing services for small and large molecules include cGMP-compliant facilities for clinical supplies, registration batches as well as commercial volumes through our API manufacturing plant & disposable Biologics manufacturing facility.

Driving our innovative culture is our highly qualified team of 4200 scientists supported by state-of-the-art infrastructure and market-leading technology. Our scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security & quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.

With 2 Mn sq ft of specialist discovery, development & manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. Smaller and virtual companies, non-profit institutions, academic centers and start-ups also collaborate with us for their research-related requirements.

Write to us at bdc@syngeneintl.com

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.

In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. It's brands hold leadership positions in sub-therapeutic areas they are present in.

In Emerging Markets, company has presences in Africa, South East Asia, West Asia, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc.

As on 31 March 2021, Ajanta has 36 ANDA approvals which are commercialised. And it is awaiting US FDA approval for 15 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.

Company has state-of-the-art research facilities for formulation and API development located at Mumbai, India. R&D capabilities are evident from number of 1st to market products launched by the company providing patients most needed compliance and convenience. A dedicated and focused team of over 650+ scientists work for R&D, which is growing continuously.

Ajanta has 6 formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, it also has an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facilities at Paithan (Maharashtra, India) and Dahej (Gujarat, India) have been approved by US FDA.

Ajanta continuously invests in enhancing the existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet company’s growth requirements.

Please visit http://ajantapharma.com/ for more information.

Ambio Pharmaceuticals is the parent company of AmbioPharm, Inc. and Ambio, Inc.

AmbioPharm was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at very small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.

Ambio is a drug development company with a rich and growing pipeline of proprietary drug development programs for bioequivalent and biosimilar versions of the world’s best-selling peptide drugs.